Skip to Content

Avalon Pharmaceuticals Announces Its Proprietary Drug Discovery and Development Platform AvalonRx(R) Identifies Potent Selective Inhibitors for the c-Myc and Beta-catenin Pathways

GERMANTOWN, Md.--(BUSINESS WIRE)--Oct 23, 2007 - Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced its proprietary drug discovery and development platform, AvalonRx(R), identified potent selective inhibitors for the c-Myc and Beta-catenin pathways. The results will be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA from 12:30pm-2:30pm and from 5:30pm-7:30pm (PDT) in posters titled:

"A biomarker based high throughput screen identifies small molecular weight modulators of the Beta-catenin pathway;"

"Biomarker based high-throughput screening for identification of small molecule inhibitors, targeting the antiproliferative property of the c-Myc signaling pathway."

"The unique capabilities of AvalonRx(R) allow us to target two of the most important, but historically "undruggable" cancer pathways, namely Myc and Beta-catenin," stated Stephen Horrigan, Ph.D., Vice President of Research. "These programs should result in the development of true "first-in-class" therapeutics with direct relevance to human disease."


AvalonRx(R) is a comprehensive, innovative and proprietary suite of technologies based upon large-scale gene expression analysis. This platform facilitates drug discovery by expanding the range of therapeutic targets for drug intervention, including targets and target pathways frequently considered intractable using conventional HTS approaches, allows more informed decisions about which compounds to advance towards clinical trials, and facilitates drug development through identification of biomarkers of efficacy that can stratify patients or provide early indicators of response.

About Avalon Pharmaceuticals

Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon's lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the Survivin and Myc pathways and partnerships with Merck, MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx(R) is the company's proprietary platform which is based on large-scale biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, MD.

Safe Harbor Statement

This announcement contains, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect the current views of Avalon management and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, risks and uncertainties, including those specified under the "Risk Factors" section of our 2006 Annual Report on Form 10-K and updates contained in subsequent filings we make with the Securities and Exchange Commission.


Avalon Pharmaceuticals, Inc.
David D. Muth
Executive Vice President &
Chief Business Officer
Fax: 301-556-9910
The Trout Group LLC
Chad Rubin, 646-378-2947

Posted: October 2007